A brand new drug candidate has proven spectacular ends in a mid-stage scientific trial for drug-resistant epilepsy, elevating hopes for sufferers who proceed to endure seizures regardless of being on a number of drugs.
Rapport Therapeutics has introduced that its experimental compound RAP-219 diminished seizures by a mean of 77.8% in a Section 2a examine, with nearly 1 / 4 of individuals remaining seizure-free over the two-month therapy interval.
The trial enrolled 30 adults with focal onset seizures, also called partial seizures – a typical type of epilepsy marked by how electrical exercise begins in a single a part of the mind. All individuals have been fitted with an implanted responsive neurostimulation (RNS) machine, which constantly monitored mind exercise and allowed researchers to measure scientific seizures and an goal electrographic marker known as “lengthy episodes.”
Sufferers started therapy on a low dose of RAP-219, growing to a day by day oral pill of 1.25 mg for the remainder of the eight-week examine. By the trial’s conclusion, 85% of sufferers had not less than a 30% drop in lengthy episodes, and 72% had their scientific seizures reduce in half or extra. Most strikingly, 24% of sufferers have been freed from seizures – one thing not often seen in a treatment-resistant inhabitants.
“We’re excited by the power of those information in each the electrographic biomarker and scientific seizure reductions,” mentioned Jeffrey Sevigny, M.D., Chief Medical Officer at Rapport Therapeutics. “These outcomes give us the arrogance to progress RAP-219 into its subsequent stage of scientific improvement.”
What makes RAP-219 totally different is its precision mechanism. It targets TARPγ8, a protein that helps regulate AMPA receptors – key gamers in excitatory mind signaling. Whereas AMPA receptors will be discovered all through the mind, TARPγ8 is concentrated within the cortex and hippocampus – the areas focal seizures usually stem from. By dampening exercise solely in these areas, RAP-219 is designed to dial down seizures with out triggering any sedating/motor operate uncomfortable side effects usually related to broader-acting medicine.
Reported uncomfortable side effects have been delicate to average, together with dizziness, headache and fatigue. No severe questions of safety emerged through the trial interval, although three sufferers discontinued as a consequence of opposed occasions.
“Importantly, the baseline traits of sufferers enrolled, along with the broad cortical expression of TARPγ8 and the sturdy ends in the trial, give us confidence within the translatability of the info into the Section 3 drug-resistant focal onset seizure affected person inhabitants,” Sevigny added. “Given the persistent unmet want in focal epilepsy, we plan to maneuver into two Section 3 trials utilizing conventional scientific seizure endpoints, with initiation anticipated within the third quarter of 2026.”
Rapport now plans to fulfill with the US Meals and Drug Administration (FDA) after which launch two essential Section 3 trials subsequent yr. The corporate can even proceed creating a long-acting injectable model as a way to deal with remedy adherence, a frequent problem in epilepsy.
“Regardless of the obtainable therapies, as much as 40% of sufferers with focal epilepsy proceed to expertise seizures,” mentioned the examine’s principal investigator Jacqueline French, M.D., a professor within the Division of Neurology at NYU Langone Well being’s Complete Epilepsy Middle. “There may be nonetheless great want for added efficient anti-seizure drugs with novel mechanisms of motion. Physicians and sufferers want new choices that ship significant advantages and the potential to supply the promise of seizure freedom.
“This trial represents the primary time a novel anti-seizure remedy was evaluated in focal seizure sufferers utilizing the RNS system with an goal biomarker of seizure exercise,” she added. “The magnitude of the discount in scientific seizure frequency seen on this trial, and the corroboration of the scientific exercise from the target biomarker, give me confidence {that a} remedy like RAP-219 has the potential to be a extremely efficient ASM for drug-resistant focal seizure sufferers.”
Round a 3rd of the 50 million individuals worldwide residing with epilepsy do not need their situation below management utilizing present remedy. Relying on the Section 3 trials, extra broadly assessing RAP-219’s efficacy and security, this drug has the potential to be a much-needed advance in seizure administration.
The newest information comes from the continued section 2a RAP-219-FOS-201 trial (NCT06377930).
Supply: Rapport Therapeutics
